Some Info:
Gilead Antiviral drug Remdesivir fails first trial— DailyFX Team Live (@DailyFXTeam) April 23, 2020
- The study did not improve the condition of the patients or reduce the presence of the disease in the bloodstream
- Study included 237 patients, 79 of which were placebos
- Gilead says data trends still show potential benefits for remediators, especially patients